Promising Umbralisib Combinations Tested in NHL Subtypes

Ariela Katz
Published: Wednesday, May 02, 2018
Bruce Cheson, MD

Bruce Cheson, MD
Patients with relapsed/refractory non-Hodgkin lymphoma (NHL) have limited options for treatment, and effective advancedstage therapies must be developed for many subtypes of the disease. In the search for solutions, investigators are turning to combination therapies.

“The study was designed to start with monotherapy treatments and move to combinations in later stages of the trial. The future cohorts will evaluate umbralisib and ublituximab for indolent lymphoma, as well,” said Cheson, who is a professor of medicine, deputy chief of hematology and oncology, and head of hematology and cellular therapy at the Lombardi Comprehensive Cancer Center.
 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x